Why a Research Platform Should Be One System, Not Twelve Tools

If you assemble a research stack the way most organizations do, you end up with a graveyard of integrations. An EDC for capture. A separate portal for patients. A mapping tool for harmonization. An analytics environment somewhere else. A safety system, a randomization vendor, a quality-monitoring add-on. Each one is reasonable on its own. Together, they form a system whose dominant activity is moving data between systems.

The seams are where the work — and the cost — actually live. Flat-file exports. Nightly reconciliation jobs. The recurring question of which copy of a patient record is the real one. Every integration is a place where data drifts, where provenance gets lost, and where a number in one tool quietly disagrees with the same number in another.

We built CuRE on the opposite bet: not a better tool, but one system.

One governed record

CuRE is twelve products across three layers. Ingestion brings clinical data, files, and patient-reported outcomes in. Infrastructure harmonizes and governs that data. Research applications — decision support, study operations, randomization, quality management, pharmacovigilance, and more — put it to work. What makes that a platform rather than a bundle is that all twelve compose on the same substrate.

Every event — a captured form, a mapped lab result, a randomization, a dispensation, a safety case — lands on one shared research record. There are no flat-file islands and no reconciliation step, because there’s nothing to reconcile: the products read and write the same governed data. When a study manager, a coordinator, and a biostatistician look at the same patient, they’re looking at the same record, with the same provenance and the same audit trail.

This is also why standards matter to us as plumbing, not branding. FHIR and SMART on FHIR bring data in from the EHR. The OMOP Common Data Model gives every source a shared structure to line up against. SDTM and CDASH carry it out to submission. The standards are what let twelve products treat the same data as one record instead of twelve copies.

AI that’s attributable, not magical

“AI-native” is an easy thing to claim and an easy thing to fake. Our version is deliberately unglamorous: AI shows up where it removes the most manual labor — extracting structure from clinical notes, classifying columns, suggesting FHIR-to-OMOP mappings, flagging validation issues, surfacing decision support at the point of care.

The non-negotiable is that it’s attributable and human-in-the-loop. Every AI-assisted action carries a confidence signal, a visible source, and a correction path. A coordinator can see why a value was suggested and override it. A data manager can trace a mapping back to its evidence. That’s the difference between practical AI with guardrails and a generative black box you have to take on faith — and in regulated research, faith doesn’t pass an audit.

Because the AI operates on the one governed record, its suggestions carry context the seam-stitched stack can’t offer. A validation prompt knows the patient’s history. A mapping suggestion knows how similar sources were mapped before. Intelligence compounds when it isn’t fragmented across tools.

Production-ready in weeks

The hidden tax of the bolted-together stack is setup time. Standing up a study means provisioning each tool, then building the integrations between them — a multi-month vendor project before a single patient is enrolled. And when the protocol changes, as it always does, the integrations have to change with it.

One system collapses that. Study build is configuration, not integration. Amendments are config diffs, not multi-week change orders routed through a vendor. Production-ready in weeks, not months — because there’s no integration layer to rebuild every time reality moves.

That speed isn’t a luxury feature. For the disease associations, academic centers, and non-profits doing some of the most important outcomes research, the choice is often between starting now and not starting at all. A platform that deploys in weeks — without an enterprise tax or per-seat surprises — changes what’s possible for the organizations that need it most.

The bet

Twelve products is a lot of surface area. The temptation is always to ship them as separate tools and let customers integrate. We think that’s exactly the mistake the industry keeps making. The value isn’t in the products — it’s in the fact that they share one record, one governance model, and one AI layer.

One system, not twelve tools. That’s the whole idea.